Sanara MedTech/SMTI

$33.65

2.28%
-
1D1W1MYTD1YMAX

About Sanara MedTech

Sanara Medtech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. It markets several products for surgical and chronic wound care applications and has multiple products in its pipeline. Its surgical products, CellerateRX Surgical, TEXAGEN, BiFORM, ACTIGEN, ALLOCYTE, ALLOCYTE Plus Advanced Viable Bone Matrix (ALLOCYTE Plus), BIASURGE, FORTIFY TRG Tissue Repair Graft (FORTIFY TRG), and FORTIFY FLOWABLE Extracellular Matrix (FORTIFY FLOWABLE) are used in a range of surgical specialties to help promote patient healing and reduce the risk of complications. CellerateRX Surgical products, TEXAGEN products, FORTIFY TRG and FORTIFY FLOWABLE are used in specialties, including cardiothoracic, colorectal, general surgery, hand, head and neck, high-risk obstetrics and gynecology, Mohs surgery, neurosurgery, and others.

Ticker

SMTI

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Zachary Fleming

Employees

107

Headquarters

Fort worth, United States

Sanara MedTech Metrics

BasicAdvanced
$291.36M
Market cap
-
P/E ratio
-$0.52
EPS
1.65
Beta
-
Dividend rate
$291.36M
1.64909
$48.41
$26.06
13.75K
1.38
1.038
20.327
21.622
-18.75%
-6.58%
-9.93%
-8.17%
4.483
6.433
41.77%
46.94%
60.95%

What the Analysts think about Sanara MedTech

Analyst Ratings

Majority rating from 1 analysts.
Buy

Price Targets

Average projection from 1 analyst.
30.76% upside
High $44.00
Low $44.00
$33.65
Current price
$44.00
Average price target

Sanara MedTech Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-1.13% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$17.6M
10%
Net income
$-200K
-80%
Profit margin
-1.13%
-81.92%

Sanara MedTech Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 76.92%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.14
-$0.22
-$0.13
-$0.03
-
Expected
-$0.33
-$0.13
$0.00
-$0.13
-$0.07
Surprise
-57.58%
69.23%
-∞%
-76.92%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Sanara MedTech stock?

Sanara MedTech (SMTI) has a market cap of $291.36M as of April 24, 2024.

What is the P/E ratio for Sanara MedTech stock?

The price to earnings (P/E) ratio for Sanara MedTech (SMTI) stock is 0 as of April 24, 2024.

Does Sanara MedTech stock pay dividends?

No, Sanara MedTech (SMTI) stock does not pay dividends to its shareholders as of April 24, 2024.

When is the next Sanara MedTech dividend payment date?

Sanara MedTech (SMTI) stock does not pay dividends to its shareholders.

What is the beta indicator for Sanara MedTech?

Sanara MedTech (SMTI) has a beta rating of 1.65. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Sanara MedTech stock price target?

The target price for Sanara MedTech (SMTI) stock is $44, which is 34.97% above the current price of $32.6. This is an average based on projections from 1 analyst, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Sanara MedTech stock

Buy or sell Sanara MedTech stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing